Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
International Journal of Chronic Obstructive Pulmonary Disease|October 3, 2022
Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care SettingDavid M G Halpin, Kieran J Rothnie, Victoria Banks, et al.Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.Advances in Therapy|July 20, 2022
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-AnalysisAfisi S Ismaila, Katrin Haeussler, Alexandrosz Czira, et al.Advances in Therapy|July 18, 2022
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-AnalysisAfisi S Ismaila, Katrin Haeussler, Alexandrosz Czira, et al.BMJ Open Respiratory Research|May 21, 2024
Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort studyKieran J Rothnie, Robert P Wood, Alexandrosz Czira, et al.ERJ Open Research|September 16, 2021
Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationaleZhenyu Liang, Nanshan Zhong, Rongchang Chen, et al.ERJ Open Research|April 8, 2025
Delaying disease progression in COPD with early escalation to triple therapy: a modelling study (DEPICT-2)Dave Singh, Diego Fabian Litewka, Joan B Soriano, et al.International Journal of Chronic Obstructive Pulmonary Disease|December 17, 2021
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY ModelSoham Shukla, Dhvani Shah, Alan Martin, et al.ERJ Open Research|November 3, 2025
Clinically important deterioration in a mild-moderate COPD populationSharmistha Biswas, Dany Doiron, Pei Zhi Li, et al.American Journal of Respiratory and Critical Care Medicine|April 5, 2022
Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease StudyJean Bourbeau, Dany Doiron, Sharmistha Biswas, et al.Pageof 8